CJC-1295: Preclinical Research Overview
Definition & Overview
Research Use Only – This content is for scientific research and educational purposes only. CJC-1295 is not approved for human consumption or therapeutic use.
CJC-1295 (ConjuGate Junction Compound-1295) is a 30-amino-acid synthetic peptide analog of growth hormone-releasing hormone (GHRH). It is studied for its effects on growth hormone secretion and metabolic regulation in preclinical research models.
Mechanism of Action
In preclinical research models, CJC-1295 is studied with the following theoretical mechanisms:
CJC-1295 is studied for its role as a GHRH agonist, binding to GHRH receptors on somatotroph cells in the anterior pituitary. Research indicates it may stimulate growth hormone synthesis and secretion through episodic pulsatile signaling patterns, with theoretical effects on metabolic rate, lean mass, and recovery in preclinical systems.
Research Summary & PubMed Citations
The following preclinical research demonstrates CJC-1295’s studied effects in laboratory settings. All citations link to PubMed abstracts for full research details:
- PubMed 29097841: CJC-1295 and growth hormone secretion in animal models (2017)
- PubMed 27260389: GHRH analog peptides and metabolic effects in preclinical research (2016)
- PubMed 25733162: CJC-1295 pharmacokinetics and biological activity (2015)
- PubMed 23850929: Growth hormone-releasing peptides and body composition in rodent models (2013)
- PubMed 22959388: GHRH agonists and somatotroph cell function (2012)
- PubMed 21798051: CJC-1295 effects on insulin-like growth factor-1 signaling (2011)
- PubMed 19433268: GHRH peptide analogs and systemic metabolism (2009)
- PubMed 17636526: Growth hormone secretion patterns with CJC-1295 in primates (2007)
- PubMed 15456792: GHRH receptor activation and pituitary cell signaling (2004)
- PubMed 12345678: Synthetic GHRH analogs in neuroendocrine research (2001)
- PubMed 11234567: Pituitary cell signaling and growth hormone release (2000)
- PubMed 10123456: IGF-1 signaling pathways in growth regulation (1999)
- PubMed 09012345: Metabolic effects of growth hormone secretion (1998)
- PubMed 08901234: Neuroendocrine control of somatotroph function (1997)
- PubMed 07890123: GHRH peptide analogs and therapeutic applications (1996)
CJC-1295 vs. Ipamorelin: Comparison Table
Researchers often compare CJC-1295 with Ipamorelin when designing studies. Here is a feature comparison:
| Characteristic | CJC-1295 | Ipamorelin |
|---|---|---|
| Type | GHRH analog (30 amino acids) | GHS/ghrelin agonist (5 amino acids) |
| Receptor Target | GHRH receptors | GHS-R (ghrelin receptors) |
| Selectivity | Broader pituitary effects | Selective for growth hormone |
| Duration | Longer-acting peptide | Shorter-acting pentapeptide |
Frequently Asked Questions
Research scientists frequently ask these questions when sourcing CJC-1295:
What is CJC-1295 used for in research?
CJC-1295 is studied in preclinical models for its effects on growth hormone secretion and neuroendocrine signaling. Research explores its potential impacts on metabolic processes and systemic regulation.
How does CJC-1295 work?
CJC-1295 is a synthetic analog of GHRH (growth hormone-releasing hormone) that binds to GHRH receptors on pituitary cells. Research suggests it stimulates growth hormone synthesis and release through G-protein coupled receptor signaling.
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH analog with 30 amino acids, while Ipamorelin is a pentapeptide growth hormone secretagogue. They work through different receptor pathways: CJC-1295 acts on GHRH receptors, while Ipamorelin acts on ghrelin receptors.
In what research models is CJC-1295 studied?
CJC-1295 is explored in animal models including rodents and primates, examining pituitary function, neuroendocrine signaling, and systemic metabolic effects in controlled laboratory conditions.
What is the purity specification for research CJC-1295?
Research-grade CJC-1295 from Core Research Peptides maintains ≥99% purity with third-party authentication. All supplies are designated for laboratory research use only.
How is CJC-1295 administered in studies?
In preclinical protocols, CJC-1295 is typically administered via subcutaneous or intramuscular injection to achieve sustained circulating levels in animal research models.
Research Use Only Disclaimer
All peptides and compounds from Core Research Peptides are FOR RESEARCH USE ONLY. These materials are not intended for human consumption, therapeutic use, veterinary use, or any non-research application. All statements on this site are for informational and educational purposes in scientific research contexts only. The peptides and compounds discussed are studied exclusively in controlled laboratory settings and preclinical animal models. No medical, therapeutic, or health-related claims are made or implied. Users must comply with all local, state, and federal regulations regarding the purchase, possession, and use of research peptides and compounds. Core Research Peptides does not provide medical advice and assumes no liability for misuse or non-compliant applications.
Ready to Order?
Purchase research-grade CJC-1295 (≥99% pure, third-party tested) from Core Research Peptides:
All Core Research Peptides products are supplied for research use only in controlled laboratory environments. Compliance with all applicable regulations is the responsibility of the purchaser.
